Natural History of Type 1 Interferonopathies: Insights From a European Cohort

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorImagine Institute

About this trial

Type I interferonopathies are rare autoinflammatory disorders caused by genetic defects and associated with significant morbidity and mortality. These diseases are refractory to conventional immunosuppressive therapies. They typically occur in childhood, although disease onset in adulthood has been observed. The clinical spectrum is wide and mainly involves the central nervous system. Joint involvement is also common, and more rarely, haematological features such as cytopenias or immunodeficiency may be observed.

Nearly all patients show consistent over-activation of the type I IFN pathway, as evidenced, the expression of IFN-stimulated genes, the so-called 'interferon signature'. To date, the natural history of interferonopathies remains unclear.

In this context, the establishment of a natural history of type I interferonopathy in patients is proposed to elucidate the pathophysiological mechanisms and identify biomarkers for diagnosis, prognosis, and disease activity, with the aim of better characterising the diversity of interferonopathies.

The main objective is to characterise the evolution of the pathology in paediatric and adult patients with type I interferonopathies.

The overall aim of this research is to propose therapeutic options tailored to patient phenotypes and to better define patient sub-groups in order to optimise the preparation of future clinical trials.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Genetically confirmed patient with type I interferonopathy

Patient affiliated to a social security scheme or beneficiary of such a scheme.

Disqualifiers

None

Trial population

Patients with genetically confirmed type I interferonopathy in Europe. 500 patients estimated.

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

Not listed

Trial groups

500 Participants
are grouped into 1 trial group
Group A: Patients

Trial outcomes

Primary outcomes

1

Characterizing disease progression in pediatric and adult patients with type I interferonopathies

Composite description of phenotypes of patients with type I interferonopathies according to genotype (clinical, biological) over time.

Time frame
2025-2045

Secondary outcomes

1

Identifing and characterising genotype-specific immunological factors

Description of specific immunological factors according to genotype

Time frame
2025-2045
2

Research of biomarkers for diagnosis, prognosis and monitoring of disease activity

Biomarkers identified for diagnosis, prognosis and monitoring of disease activity

Time frame
2025-2045
3

Monitoring of treatment response according to phenotype and genotype

Treatment response by phenotype and genotype

Time frame
2025-2045

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.